Checkpoint Therapeutics CEO sells $3.07 million in inventory

Moreover, on December 20, Oliviero transferred 900,000 shares into an irrevocable belief for his minor youngsters. This switch was executed without charge, and Oliviero doesn’t have funding management over the securities held by the belief. Following these transactions, Oliviero retains possession of two,294,583 shares of Checkpoint Therapeutics (NASDAQ:CKPT). InvestingPro subscribers can entry further insights, together with 8 extra key funding ideas and detailed monetary well being metrics for CKPT. InvestingPro subscribers can entry further insights, together with 8 extra key funding ideas and detailed monetary well being metrics for CKPT.

Moreover, on December 20, Oliviero transferred 900,000 shares into an irrevocable belief for his minor youngsters. This switch was executed without charge, and Oliviero doesn’t have funding management over the securities held by the belief. Following these transactions, Oliviero retains possession of two,294,583 shares of Checkpoint Therapeutics.

In different latest information, Checkpoint Therapeutics has been the main focus of a number of vital developments. Earnings per share for the second quarter surpassed each agency and consensus estimates at ($0.18). As well as, the corporate secured a further $12 million from a latest providing.

Checkpoint Therapeutics additionally reported promising outcomes from its cosibelimab trial, with goal response charges surpassing earlier observations. The corporate has set a Prescription Drug Person Price Act purpose date for December 28, 2024, for the Biologics License Software for cosibelimab.

Lake Road Capital Markets upgraded Checkpoint Therapeutics’ worth goal from $4 to $7 whereas sustaining a Purchase ranking. The agency expressed confidence within the firm’s continued progress into 2025. In the meantime, H.C. Wainwright reiterated a Purchase ranking on the inventory, highlighting the potential market alternative for cosibelimab.

In different firm information, Checkpoint Therapeutics introduced a inventory sale anticipated to generate roughly $12 million and a partnership with GC Cell to judge the mixture of their most cancers therapies. These are among the many latest developments in Checkpoint Therapeutics’ ongoing efforts within the subject of immunotherapy and focused oncology.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.